Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Clinical predictors of treatment failure for diabetic foot infections: data from a prospective trial.

Lipsky BA, Sheehan P, Armstrong DG, Tice AD, Polis AB, Abramson MA.

Int Wound J. 2007 Mar;4(1):30-8.

PMID:
17425547
2.

Ertapenem versus piperacillin/tazobactam for diabetic foot infections (SIDESTEP): prospective, randomised, controlled, double-blinded, multicentre trial.

Lipsky BA, Armstrong DG, Citron DM, Tice AD, Morgenstern DE, Abramson MA.

Lancet. 2005 Nov 12;366(9498):1695-703.

PMID:
16291062
3.

Treating diabetic foot infections with sequential intravenous to oral moxifloxacin compared with piperacillin-tazobactam/amoxicillin-clavulanate.

Lipsky BA, Giordano P, Choudhri S, Song J.

J Antimicrob Chemother. 2007 Aug;60(2):370-6. Epub 2007 Jun 6.

PMID:
17553812
4.

An open-label, randomized study comparing efficacy and safety of intravenous piperacillin/tazobactam and ampicillin/sulbactam for infected diabetic foot ulcers.

Harkless L, Boghossian J, Pollak R, Caputo W, Dana A, Gray S, Wu D.

Surg Infect (Larchmt). 2005 Spring;6(1):27-40.

PMID:
15865549
5.

Comparative costs of ertapenem and piperacillin-tazobactam in the treatment of diabetic foot infections.

Tice AD, Turpin RS, Hoey CT, Lipsky BA, Wu J, Abramson MA.

Am J Health Syst Pharm. 2007 May 15;64(10):1080-6.

PMID:
17494908
6.

Piperacillin/tazobactam versus imipenem/cilastatin for severe diabetic foot infections: a prospective, randomized clinical trial in a university hospital.

Saltoglu N, Dalkiran A, Tetiker T, Bayram H, Tasova Y, Dalay C, Sert M.

Clin Microbiol Infect. 2010 Aug;16(8):1252-7. doi: 10.1111/j.1469-0691.2009.03067.x. Epub 2009 Oct 14.

7.
8.

Microbiological and clinical characteristics of diabetic foot infections in northern India.

Tiwari S, Pratyush DD, Dwivedi A, Gupta SK, Rai M, Singh SK.

J Infect Dev Ctries. 2012 Apr 13;6(4):329-32.

9.

Ertapenem versus piperacillin/tazobactam for the treatment of complicated infections: a meta-analysis of randomized controlled trials.

An MM, Zou Z, Shen H, Zhang JD, Chen ML, Liu P, Wang R, Jiang YY.

BMC Infect Dis. 2009 Dec 2;9:193. doi: 10.1186/1471-2334-9-193.

10.

Post-treatment leukocytosis predicts an unfavorable clinical response in patients with moderate to severe diabetic foot infections.

Fleischer AE, Wrobel JS, Leonards A, Berg S, Evans DP, Baron RL, Armstrong DG.

J Foot Ankle Surg. 2011 Sep-Oct;50(5):541-6. doi: 10.1053/j.jfas.2011.04.023. Epub 2011 May 31.

PMID:
21621432
11.

Treatment of polymicrobial infections: post hoc analysis of three trials comparing ertapenem and piperacillin-tazobactam.

Solomkin J, Teppler H, Graham DR, Gesser RM, Meibohm AR, Roy S, Woods GL.

J Antimicrob Chemother. 2004 Jun;53 Suppl 2:ii51-7.

PMID:
15150183
12.

Does dermal thermometry predict clinical outcome in diabetic foot infection? Analysis of data from the SIDESTEP* trial.

Armstrong DG, Lipsky BA, Polis AB, Abramson MA.

Int Wound J. 2006 Dec;3(4):302-7.

PMID:
17199766
13.

Efficacy and safety of neutral pH superoxidised solution in severe diabetic foot infections.

Martínez-De Jesús FR, Ramos-De la Medina A, Remes-Troche JM, Armstrong DG, Wu SC, Lázaro Martínez JL, Beneit-Montesinos JV.

Int Wound J. 2007 Dec;4(4):353-62. Epub 2007 Oct 22.

PMID:
17953678
14.

Predictive model of short-term amputation during hospitalization of patients due to acute diabetic foot infections.

Barberán J, Granizo JJ, Aguilar L, Alguacil R, Sainz F, Menéndez MA, Giménez MJ, Martínez D, Prieto J.

Enferm Infecc Microbiol Clin. 2010 Dec;28(10):680-4. doi: 10.1016/j.eimc.2009.12.017. Epub 2010 May 31.

PMID:
20570020
15.

Ertapenem versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections: results of a double-blind, randomized comparative phase III trial.

Solomkin JS, Yellin AE, Rotstein OD, Christou NV, Dellinger EP, Tellado JM, Malafaia O, Fernandez A, Choe KA, Carides A, Satishchandran V, Teppler H; Protocol 017 Study Group.

Ann Surg. 2003 Feb;237(2):235-45.

16.

Topical application of a gentamicin-collagen sponge combined with systemic antibiotic therapy for the treatment of diabetic foot infections of moderate severity: a randomized, controlled, multicenter clinical trial.

Lipsky BA, Kuss M, Edmonds M, Reyzelman A, Sigal F.

J Am Podiatr Med Assoc. 2012 May-Jun;102(3):223-32. Erratum in: J Am Podiatr Med Assoc. 2012 Jul-Aug;102(4):323.

PMID:
22659765
17.

Diabetic foot infection: a critical review of recent randomized clinical trials on antibiotic therapy.

Crouzet J, Lavigne JP, Richard JL, Sotto A; Nîmes University Hospital Working Group on the Diabetic Foot (GP30).

Int J Infect Dis. 2011 Sep;15(9):e601-10. doi: 10.1016/j.ijid.2011.05.003. Epub 2011 Jul 6. Review.

18.

Outcome of diabetic foot infections treated conservatively: a retrospective cohort study with long-term follow-up.

Pittet D, Wyssa B, Herter-Clavel C, Kursteiner K, Vaucher J, Lew PD.

Arch Intern Med. 1999 Apr 26;159(8):851-6.

PMID:
10219931
19.

Piperacillin/tazobactam-induced neutropenia, thrombocytopenia, and fever during treatment of a diabetic foot infection.

Uzun G, Onem Y, Hatipoglu M, Turhan V, Mutluoglu M, Ay H.

Scand J Infect Dis. 2013 Jan;45(1):73-6. doi: 10.3109/00365548.2012.697638. Epub 2012 Jul 1.

PMID:
22746695
20.

Clinafloxacin versus piperacillin-tazobactam in treatment of patients with severe skin and soft tissue infections.

Siami G, Christou N, Eiseman I, Tack KJ; Severe Skin and Soft Tissue Infections Study Group.

Antimicrob Agents Chemother. 2001 Feb;45(2):525-31.

Supplemental Content

Support Center